Oesophageal cancer management guidelines for Uganda by Galukande, M et al.
East and Central African Journal of Surgery   http://www.bioline.org.br/js 
 
132
Oesophageal Cancer Management guidelines for Uganda 
 
M. Galukande1, A. Luwaga2, J. Jombwe1, B.D. Mugisa1, P. Baguma2, J.B. Kigula-Mugambe2,           
J. Faulal1, E. Kiguli-Malwadde2, J. Orem3, A. Gakwaya1 
1Surgery department, Faculty of Medicine, Makerere University 
2Radiotherapy department, Faculty of Medicine, Makerere University, 3Uganda Cancer Institute  




In Uganda, Oesophageal cancer is the third commonest malignancy in men and the fourth 
commonest in women, with an age standardized incidence rate of 13 - 14 per 100,000 of the 
population1,2. It remains a challenging tumour to treat with many patients presenting with 
advanced disease3,4. The currently accepted most appropriate approach to the management of 
Oesophageal cancer and that deemed available and accessible in Uganda is outlined in this 
document. Members of the Uganda Cancer Working Group have compiled it. 
 
Presenting Clinical Features 
 
There are early but few indicative warning symptoms indicative of the development of 
Oesophageal cancer. They should be treated as suspicious and merit serious assessment, with 
full history, physical examination and referral for possible investigations. They include, 
persistent heartburn/reflux, belching, cough, ear pain and unexplained persistent chest 
pain5,6,7,8. The late symptoms and signs which are  the more usual presentation of advanced 
disease include progressive dysphagia, choking sensation, anorexia, weight loss, drooling of 
saliva, odynophagia. and symptoms of metastatic disease e.g. Right upper chondrial pain3,5,6,9 
 
Diagnostic Investigations  
 
The most appropriate investigations for diagnosis include barium swallow and upper 
gastrointestinal endoscopy. In early disease, double contrastbarium studies may demonstrate 
irregular mucosal pattern3,10. In late disease, the barium swallow will typically show narrowing 
of the lumen of the oesophagus with restriction of barium flow, proximal dilatation and the 
classical ‘shouldering’ sign and a ‘rat tail’ appearance distally.  
 
Upper Gastrointestinal Endoscopy11 provides direct visualization of the oesophageal mucosa 
and allows biopsy of any suspicious areas, evaluation of anatomical extent of gross disease and 
assists in planning therapy. Abnormalities that indicate possible underlying malignancy include 
hyperemia, mucosal irregularity, ulceration and / or a frank mass with constriction of the 
oesophageal lumen. Balloon cytology (where available) allows mucosal samples to be taken in 
symptomatic patients where no mucosal irregularities are identified. Although barium swallow 
and upper GIT endoscopy are most appropriate, they are costly for the average Ugandan and 
only accessible in some public referral and private hospitals in the country.  
 
Pathology 
Minimum information12, 13, 14 required from biopsy report include:  
• Dysplasia - mild, moderate or severe 
• Histological subtype - e.g. squamous cell carcinoma, adenocarcinoma, or other more 
unusual subtypes e.g. carcinosarcoma, melanoma, Kaposi's sarcoma.  
• Tumour grade - well, moderately and poorly differentiated. 
 
And where possible (usually from operative specimens): 
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• Depth of penetration and involvement of adjacent structures:   = Tumour (T) staging  
• Lymph node involvement: = Nodal (N) staging 
• Distance of tumour from resected margins. 
 
Staging Investigations3, 15, 16, 17 
The staging system preferred is the UICC Staging system18 (see appendix I) 
 
Information required to thoroughly stage the tumour is supplied by:  
• Clinical evaluation - history and examination  
• Chest physicians assessment / physiotherapy review if for surgery  
• Baseline blood tests including full Haemogram, renal and liver function tests 
• Barium swallow - to establish tumour length in cases where endoscopy is unable to pass, 
to assess any distortion of the axis of the oesophagus and to demonstrate any fistula 
formations   
• Plain Chest Radiograph - to exclude distant metastases (especially lung) 
• Abdominal Ultrasound scan - to exclude distant metastases (when CT is unavailable) 
• Fiber optic bronchoscopy for upper / middle third lesions to exclude spread to adjacent 
structures 
• Endoluminal ultrasound (where available) - to establish depth of invasion and lymph 
node involvement 
• CT scans of the thorax and upper abdomen (when available) 
• MRI (when available) 
• PET Scan 
 
Management of early stage disease3, 10 
 
Surgery  
For patients who are appropriately staged, this remains the best chance of cure and should 
therefore always be considered. The criteria for a radical resection considers the following 
points: Good nutritional status, ECOG performance status 0,1 or 2 (see Appendix II), Adequate 
cardiac, pulmonary and renal function and tumour <3cm in length ( the absolute maximum being 
5cm).The other factors considered are that there are no signs of local spread to adjacent 
structures, and no signs of distant metastases. It may be considered inappropriate if the patient is 
more than 60years old, but always case dependent. 
 
Facilities should be available for appropriate post-operative care (this includes Intensive care, 
physiotherapy and hyper alimentation supplements). Keep the patient nil by mouth for 4 days 
(greatest risk of leakage), then start oral sips. The surgical approach will be decided by the 
Surgeon and is dependent on site of primary (see Appendix III). 
Neoadjuvant Chemotherapy19, 20, 21, 22 
There is now evidence of chemo responsiveness in esophageal cancer. In the neoadjuvant 
setting, for patients with an operable tumour who are fit enough for chemotherapy (normal 
cardiac, renal and hepatic function) and who have the resources for financing the treatment, they 
should be referred to the oncologists for consideration of pre-operative chemotherapy with 
Cisplatin and 5-Fluorouracil. For criteria for referral and chemotherapy details, (appendix IV). 
 
Chemoradiotherapy23, 24, 25  
Patients who are unsuitable for surgery e.g. due to high anesthetic surgical risk from poor 
cardiac or respiratory function, but suitable for radiotherapy given with curative intent and who 
fulfill the same criteria for chemotherapy as stated above (adequate renal, liver, bone marrow 
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and cardiac function; and who have resources) consideration should be made for chemo 
radiotherapy as the best treatment option 3. Appendix V gives details of criteria for referral and 
chemo radiotherapy. 
 
Radiotherapy26, 27, 28, 29, 30 
When patients are unsuitable for surgery, they may be suitable for radiotherapy alone given 
with curative intent. This will be with a 6-week course of external beam radiotherapy, treatment 
given on a daily basis. (Appendix VI). 
 
Management of advanced disease / Palliative care26, 27, 28, 29, 30 
 For patients with metastatic or locally advanced disease where cure is deemed impossible, 
palliation of symptoms is the priority. Symptoms frequently needing treatment include 
dysphasia and Odynophagia. the approach to each is outlined here under: 
 
Dysphagia  
This is one of the main symptoms of advanced oesophageal carcinoma. Dysphagia refers to 
difficulty in swallowing. Dysphagia is initially to solids when the oesophageal lumen is reduced 
to 12 mm or less progressing to dysphagia to liquids, and possibly total obstruction with pooling 
and drooling of saliva30 (see appendix VII for dysphagia scoring system). Aspiration of pooled 
oesophageal contents can lead to choking and possibly aspiration pneumonia.  
Management options for dysphagia include:  
• Bougie dilatation alone or used prior to stenting 
• Stenting31 with expandable metal mesh stent, Celestine tube or 'Mulago' tube or 
• Palliative radiotherapy32 
• Pharmacological measures 
(Appendix VIII) 
Mulago tube (Oesophageal intubation 33) 
This is a modified Celestine tube and requires a general anesthetic and laparotomy for insertion. 
Many patients develop significant reflux symptoms after insertion and are thus given the 
following advice: 
• Eat small frequent meals.  
• Remain upright for at last 1 hour after eating 
• When sleeping, raise the head end of the bed 
• Avoid heavy physical work, which may increase the intra-abdominal pressure. Distal  
migration of the tube is a recognized complication of this tube insertion30, 34 
 
Palliative Radiotherapy35 
This is delivered with external beam radiotherapy. The dose and fractionation will depend on the 
performance status of the patient, prognosis and length of field to be irradiated (Appendix VI). 
The use of Brachytherapy treatment with endoluminal sources may become available as a 
treatment option in the future in Uganda36. 
 
Pharmacological measures  
The above surgical, radio therapeutic and intubation interventions are important and are aimed at 
maintaining the oesophageal lumen, to maintain swallowing of food. In addition some drug 
measures can help. Dexamethasone (7-day trial) 4-12 mg in the morning, with either Nystatin 
100,000 units/ ml, 1-2 ml tds, or Ketoconazole 200 mg daily for 7 days.  
Oral drugs may not be possible when there is total obstruction of the lumen. 
 
Odynophagia – Painful swallowing 
Discomfort or pain may be felt retrosternally, in the neck or between the shoulder blades 
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together with dysphagia. It ranges from mild to moderate or severe pain. Management options 
maintain oesophageal lumen as above and WHO analgesic ladder for somatic pain37, 38, 39, 40 (See 
Appendix IX) 
  
Reflux - with or without heartburn  
Management options: 
• Position patient upright to eat, and maintain position for at least 15 minutes (if no tube) 
after feeding Antacids e.g. magnesium trisilicate 10mls tds 
• Dietary advice: 
• Frequent small meals 
• Position as above, with feeding assistant facing the patient so that they can see 
each other. 
• Food should be cooked until soft and mashed or mixed with soup. 
• Patient should be advised to eat slowly, and to take sips of water in between 
mouthfuls. 
 
Drooling of saliva 
Anticholinergic drugs can help relieve excessive salivation or drooling:  
• Hyoscine Butyl bromide SC. 10 - 20 mg bd - tds 
• Amitryptilline 12.5 mg od or bd orally 
• Antihistaminic antiemetics e.g. Cyclizine 50 mg tds subcutaneously or orally. 
 
Choking sensation  




This is due to the local effects of dysphagia and odynophagia in addition to the systemic effects 
of advanced cancer42. Appetite can sometimes be improved by the use of low dose steroids, e.g 
Dexamethasone 2mg orally od or Prednisolone 10mg orally od. Insertion of a feeding 
gastrostomy tube or a percutaneous entero-gastrostomy (pEG) can assist in the nutritional 
supportive management of patients with severe dysphagia43. It is also useful to build up the 
strength of patients prior to more intensive planned treatment such as surgery or higher dose 
radiotherapy. 
 
Psychosocial and Spiritual aspects44, 45 
Palliative care aims to achieve the best quality of life for patients and their families with control 
of not only pain and other physical symptoms but also psychological, social and spiritual aspects 
of their health. Many aspects of palliative care are applicable early in the course of a patient's 





Both patient and relatives may be anxious that the patient will starve to death. Efforts should be 
taken as above to maintain the oesophageal lumen. Counseling includes distinguishing between 
eating for nutritional purposes and for pleasure. When the former goal is no longer possible, the 
patient can still chew their favourite food and spit it out. Acute anxiety and agitation in the last 
few hours of life may require sedation with diazepam. 
 
Low Self Esteem 
Drooling, dependency on others for feeding, food remaining on clothes, as well as loss of 
employment and other social issues may all contribute to low self-esteem. Independence should 
East and Central African Journal of Surgery   http://www.bioline.org.br/js 
 
136
be encouraged as much as possible, and occupational therapy can help in reassessment of skills 
such as those required for activities of daily living. Counseling can help the patient accept new 
levels of dependency without loss of self-esteem. 
 
Sexuality 
Prolonged illness, weakness and low self-esteem may all affect sexuality. Health workers should 
be aware of this, and avail opportunities for open, honest discussions for the patient and partner. 
 
Spiritual issues: 
Fear of Death 
This is a common and natural part of life and the dying process. The patient and family may find 
comfort in prayer and referral for spiritual counseling from their religious leader of choice. 
 
Conclusion  
Following the above discussion, the mainstay of treatment is Surgery, Radiotherapy, 
and Chemotherapy, while we endeavor to explore the strategy of primary prevention 
from an understanding of the aetiology of  this malignancy .. Update of these 
guidelines will be ongoing. 
 
 
Appendix I - International 'Union against Cancer (UICC) Staging System Tumor, Node, 
Metastasis (TNM) System for Oesophageal Cancer 
 
Primary tumor 
TX: Primary tumor cannot be assessed 
T0: No evidence of primary tumor 
Tis: Carcinoma in situ 
TI: Tumor invades lamina propria or submucosa  
T2: Tumor invades muscularis propria 
T3: Tumor invades adventitia 
T4: Tumor invades adjacent structures 
 
Lymph node 
NX: Regional nodes cannot be assessed N0: 
No regional lymph node metastasis NI: 




M0: No distant metastasis 
MI: Distant metastasis (including positive celiac nodes) 
 
 
Tumor Stages for Oesophageal Cancer 
 
Stage 0: Tis N0 M0 
Stage I: TI N0 M0 
Stage IIA: 1'2 N0 M0; T3 N0 M0 
Stage IIB TI NI M0; T2 NI M0  
Stage III T3 Nt M0; T4 Any N M0 
Stage IV: Any T Any N Mt 
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Appendix II- Eastern Cooperative Oncology Group (ECOG) Performance Status 
 
0 Asymptomatic 
1 Symptomatic; fully ambulatory 
2 Symptomatic; in bed less than 50% of the day 
3 Symptomatic; in bed more than 50% of the day, but not bedridden 4 
Bedridden  
 
Appendix III - Surgical Approach according to site 
Site  Procedure  
Cricoid 3 stage operation; laparotomy, thoracotomy and neck incision; generally 
results as good as when radiotherapy is used alone 
Upper 1/3 2 stage operation; laparotomy and right thoracotomy approach; usually 
presents late so <10% respectable 
Middle 1/3 Right thoracotomy approach; oesophagogastrectomy and pull-up; any 




1/5 of the stomach respected in addition to the oesophageal cancer; 
splenectomy performed as well due to the proximity of splenic vessels 
 
Appendix IV - Referral criteria for Neoadjuvant chemotherapy 
Criteria for referral to the oncologists for consideration of neoadjuvant / pre-operative 
chemotherapy prior to undergoing attempted curative resection of oesophageal tumour: Tumour 
respectable with curative intent, as deemed by the appropriate surgeons. Should have completed 
the following tests: Endoscopy, Barium swallow, CT scan - when available, Histological 
Confirmation of cancer 
No evidence of metastatic disease, as evidenced by normal results from the following tests: 
Chest Radiograph, Ultrasound scan of the abdomen 
Fitness for chemotherapy with adequate renal, liver, bone marrow and cardiac function with the 




Cisplatin: 80mg/m2, IV over 4 hours with pre and post hydration, Day I, 5-Fluorouracil: 1g/m2, 
IV bolus, Day 1-4 
 
Adjuvants 
Ondansetron 8mg orally bd for 2days with each dose of Cisplatin 
Dexamethasone 8mg IV bolus and 8mg bd orally for 2 days 
Metaclopramide I0mg IV bolus, then 10mg orally tds as required 
 
This is repeated at 3 weeks for 2 cycles of treatment and then the patient should be 
scheduled for surgery at 3-6weeks after 2nd dose. 
 
Appendix V - Chemoradiation 
Criteria for referral the same as for neoadjuvant chemotherapy - see Appendix III 
Radiotherapy dose - 50 Gy in 25 daily fractions of 2 Gy each 
Concurrent chemotherapy 
Cisplatin: 80mg/m2, IV over 4 hrs with pre and post hydration, Day I & 28 
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5-Fluorouracil, 1g/m2, IV bolus, Day 1-4 & 28-31 
Adjuvants 
Ondansetron 8mg orally bd for 2/7 with each dose of Cisplatin or Metaclopromide 10mg 
IV bolus, then 10mg orally tds as required 
Dexamethasone 8mg IV bolus and 8mg bd orally 2/7 
 
Appendix VI- Radiotherapy Details 
Radical/curative Radiotherapy 
Criteria for curative radiotherapy for oesophageal tumour:  
ECOG performance status 0,1 or 2 
Non-metastatic disease 
Localised tumour < 5cm in length 
Squamous cell histology  
Age < 70 years 
 
Adequate nutritional/medical status 
Dose and fractionation schedules 
64Gy in 32 daily fractions of 2Gy each when radiotherapy given alone 40Gy 
given by anterior and posterior fields 
24Gy given by right and left laterals fields 
 
Palliative Radiotherapy 
Dose and fractionation depends on performance status / fitness of the patient, prognosis and 
length of field to be irradiated. Options include:  
8Gy in a single fraction 
20Gy in 5 daily fractions of 4Gy each 
30Gy in 10 daily fractions of 3Gy each 
 




Appendix VII - Dysphagia Scoring 2 
0 Able to swallow all solids without difficulty 
 
1 Difficulty with swallowing some hard solids or particular foods 
 
2 Able to swallow a semi-solid or liquid diet only 
 
3 Able to swallow a liquid diet only 
 
4 Unable to swallow liquids or saliva 
 
 
Appendix VIII - Therapy option according to site and severity of obstruction 
Site  Severity  Treatment  
Upper third  Grade 4 Radiotherapy 
 Grade < 3 Dilation & stenting with or without radiotherapy 
Middle third Grade 4 Dilating & stenting if possible, otherwise Radiotherapy 
 Grade < 3 Dilation & stenting with or without Radiotherapy 
Lower third Any grade  Stenting often with the Mulago tube with or without 
radiotherapy 
 




Appendix IX - WHO Analgesic ladder 
Step 1 Paracetamol tabs or syrup 1g tds and / or 
Step 2 Codeine phosphate 30 mg tds or 
Step 3 Liquid morphine 5 mg / 5 ml; Starting dose: 5 ml 4 hourly with 10 ml nocte if adult of 
normal weight (> 50 kg), if moderately to severely wasted, then start with 2.5 ml 4hrly with 5 ml 
nocte. If pain persists, the dose of morphine can be increased slowly to titrate with pain. Always 
prescribe a laxative together with opiates (Step 2 & 3), as they cause constipation, except if the 
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